journal
https://read.qxmd.com/read/33449824/risk-based-selection-of-individuals-for-oral-cancer-screening
#1
Li C Cheung, Kunnambath Ramadas, Richard Muwonge, Hormuzd A Katki, Gigi Thomas, Barry I Graubard, Partha Basu, Rengaswamy Sankaranarayanan, Thara Somanathan, Anil K Chaturvedi
PURPOSE: We evaluated proof of principle for resource-efficient, risk-based screening through reanalysis of the Kerala Oral Cancer Screening Trial. METHODS: The cluster-randomized trial included three triennial rounds of visual inspection (seven clusters, n = 96,516) versus standard of care (six clusters, n = 95,354) and up to 9 years of follow-up. We developed a Cox regression-based risk prediction model for oral cancer incidence. Using this risk prediction model to adjust for the oral cancer risk imbalance between arms, through intention-to-treat (ITT) analyses that accounted for cluster randomization, we calculated the relative (hazard ratios [HRs]) and absolute (rate differences [RDs]) screening efficacy on oral cancer mortality and compared screening efficiency across risk thresholds...
January 15, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33449816/phase-ii-trial-of-costimulation-blockade-with-abatacept-for-prevention-of-acute-gvhd
#2
Benjamin Watkins, Muna Qayed, Courtney McCracken, Brandi Bratrude, Kayla Betz, Yvonne Suessmuth, Alison Yu, Shauna Sinclair, Scott Furlan, Steven Bosinger, Victor Tkachev, James Rhodes, Audrey Grizzle Tumlin, Alexandria Narayan, Kayla Cribbin, Scott Gillespie, Ted A Gooley, Marcelo C Pasquini, Kyle Hebert, Urvi Kapoor, Andre Rogatko, Mourad Tighiouart, Sungjin Kim, Catherine Bresee, Sung W Choi, Jeffrey Davis, Christine Duncan, Roger Giller, Michael Grimley, Andrew C Harris, David Jacobsohn, Nahal Lalefar, Maxim Norkin, Nosha Farhadfar, Michael A Pulsipher, Shalini Shenoy, Aleksandra Petrovic, Kirk R Schultz, Gregory A Yanik, Edmund K Waller, John E Levine, James L Ferrara, Bruce R Blazar, Amelia Langston, John T Horan, Leslie S Kean
PURPOSE: Severe (grade 3-4) acute graft-versus-host disease (AGVHD) is a major cause of death after unrelated-donor (URD) hematopoietic cell transplant (HCT), resulting in particularly high mortality after HLA-mismatched transplantation. There are no approved agents for AGVHD prevention, underscoring the critical unmet need for novel therapeutics. ABA2 was a phase II trial to rigorously assess safety, efficacy, and immunologic effects of adding T-cell costimulation blockade with abatacept to calcineurin inhibitor (CNI)/methotrexate (MTX)-based GVHD prophylaxis, to test whether abatacept could decrease AGVHD...
January 15, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33449813/eprenetapopt-apr-246-and-azacitidine-in-tp53-mutant-myelodysplastic-syndromes
#3
David A Sallman, Amy E DeZern, Guillermo Garcia-Manero, David P Steensma, Gail J Roboz, Mikkael A Sekeres, Thomas Cluzeau, Kendra L Sweet, Amy McLemore, Kathy L McGraw, John Puskas, Ling Zhang, Jiqiang Yao, Qianxing Mo, Lisa Nardelli, Najla H Al Ali, Eric Padron, Greg Korbel, Eyal C Attar, Hagop M Kantarjian, Jeffrey E Lancet, Pierre Fenaux, Alan F List, Rami S Komrokji
PURPOSE: Approximately 20% of patients with TP53 -mutant myelodysplastic syndromes (MDS) achieve complete remission (CR) with hypomethylating agents. Eprenetapopt (APR-246) is a novel, first-in-class, small molecule that restores wild-type p53 functions in TP53 -mutant cells. METHODS: This was a phase Ib/II study to determine the safety, recommended phase II dose, and efficacy of eprenetapopt administered in combination with azacitidine in patients with TP53 -mutant MDS or acute myeloid leukemia (AML) with 20%-30% marrow blasts (ClinicalTrials...
January 15, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33449799/five-year-outcomes-from-the-randomized-phase-iii-trials-checkmate-017-and-057-nivolumab-versus-docetaxel-in-previously-treated-non-small-cell-lung-cancer
#4
Hossein Borghaei, Scott Gettinger, Everett E Vokes, Laura Q M Chow, Marco Angelo Burgio, Javier de Castro Carpeno, Adam Pluzanski, Oscar Arrieta, Osvaldo Arén Frontera, Rita Chiari, Charles Butts, Joanna Wójcik-Tomaszewska, Bruno Coudert, Marina Chiara Garassino, Neal Ready, Enriqueta Felip, Miriam Alonso García, David Waterhouse, Manuel Domine, Fabrice Barlesi, Scott Antonia, Markus Wohlleber, David E Gerber, Grzegorz Czyzewicz, David R Spigel, Lucio Crino, Wilfried Enst Erich Eberhardt, Ang Li, Sathiya Marimuthu, Julie Brahmer
PURPOSE: Immunotherapy has revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in overall survival (OS) and favorable safety versus docetaxel in patients with previously treated, advanced squamous and nonsquamous NSCLC, respectively. We report 5-year pooled efficacy and safety from these trials. METHODS: Patients (N = 854; CheckMate 017/057 pooled) with advanced NSCLC, ECOG PS ≤ 1, and progression during or after first-line platinum-based chemotherapy were randomly assigned 1:1 to nivolumab (3 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until progression or unacceptable toxicity...
January 15, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33444116/randomized-phase-ii-study-of-bevacizumab-in-combination-with-carboplatin-plus-paclitaxel-in-patients-with-previously-untreated-advanced-mucosal-melanoma
#5
Xieqiao Yan, Xinan Sheng, Zhihong Chi, Lu Si, Chuanliang Cui, Yan Kong, Bixia Tang, Lili Mao, Xuan Wang, Bin Lian, Siming Li, Xue Bai, Li Zhou, Jie Dai, Hong Yao, Jun Guo
PURPOSE: Mucosal melanoma (MM) is a highly vascularized tumor with an extremely poor prognosis. In this randomized, open-label, phase II study, we characterized the efficacy and safety of bevacizumab in combination with carboplatin plus paclitaxel (CPB) in patients with previously untreated advanced MM. PATIENTS AND METHODS: Patients were randomly assigned in a 2:1 ratio to receive carboplatin (area under the curve, 5) plus paclitaxel (175 mg/m2 ) once every 4 weeks in combination with (CPB arm, 5 mg/kg) or without (CP arm) bevacizumab once every 2 weeks...
January 14, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33444082/reply-to-a-k-agrawal-et-al
#6
Kimberly P Dunsmore, Stuart S Winter, Meenakshi Devidas, Naomi J Winick, William L Carroll, Stephen P Hunger
No abstract text is available yet for this article.
January 14, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33444081/bruton-tyrosine-kinase-inhibitors-in-waldenstrom-macroglobulinemia-unprecedented-clinical-activity-and-promising-future-directions
#7
EDITORIAL
Roger G Owen
No abstract text is available yet for this article.
January 14, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33444080/development-and-validation-of-a-risk-tool-for-predicting-severe-toxicity-in-older-adults-receiving-chemotherapy-for-early-stage-breast-cancer
#8
Allison Magnuson, Mina S Sedrak, Cary P Gross, William P Tew, Heidi D Klepin, Tanya M Wildes, Hyman B Muss, Efrat Dotan, Rachel A Freedman, Tracey O'Connor, William Dale, Harvey J Cohen, Vani Katheria, Anait Arsenyan, Abrahm Levi, Heeyoung Kim, Supriya Mohile, Arti Hurria, Can-Lan Sun
PURPOSE: Limited tools exist to predict the risk of chemotherapy toxicity in older adults with early-stage breast cancer. METHODS: Patients of age ≥ 65 years with stage I-III breast cancer from 16 institutions treated with neoadjuvant or adjuvant chemotherapy were prospectively evaluated for geriatric and clinical features predictive of grade 3-5 chemotherapy toxicity. Logistic regression with best-subsets selection was used to identify and incorporate independent predictors of toxicity into a model with weighted variable scoring...
January 14, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33444079/subcutaneous-rituximab-minichop-compared-with-subcutaneous-rituximab-minichop-plus-lenalidomide-in-diffuse-large-b-cell-lymphoma-for-patients-age-80-years-or-older
#9
Lucie Oberic, Frederic Peyrade, Mathieu Puyade, Christophe Bonnet, Peggy Dartigues-Cuillères, Bettina Fabiani, Philippe Ruminy, Hervé Maisonneuve, Julie Abraham, Catherine Thieblemont, Pierre Feugier, Gilles Salles, Fontanet Bijou, Gian-Matteo Pica, Gandhi Damaj, Corinne Haioun, René-Olivier Casasnovas, Hassan Farhat, Ronan Le Calloch, Agathe Waultier-Rascalou, Sandra Malak, Jerome Paget, Elodie Gat, Hervé Tilly, Fabrice Jardin
PURPOSE: The prognosis of elderly patients with diffuse large B-cell lymphoma (DLBCL) is worse than that of young patients. An attenuated dose of chemotherapy-cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-miniCHOP)-is a good compromise between efficacy and safety in very elderly patients. In combination with R-CHOP (R2-CHOP), lenalidomide has an acceptable level of toxicity and may mitigate the negative prognosis of the non-germinal center B-cell-like phenotype...
January 14, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33444071/nelarabine-in-pediatric-and-young-adult-t-cell-acute-lymphoblastic-leukemia-clearly-beneficial
#10
LETTER
Anurag K Agrawal, Jennifer Michlitsch, Carla Golden, Caroline A Hastings, Robert Raphael, James H Feusner
No abstract text is available yet for this article.
January 14, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33439748/lenalidomide-epoetin-alfa-versus-lenalidomide-monotherapy-in-myelodysplastic-syndromes-refractory-to-recombinant-erythropoietin
#11
Alan F List, Zhuoxin Sun, Amit Verma, John M Bennett, Rami S Komrokji, Kathy McGraw, Jaroslaw Maciejewski, Jessica K Altman, Puneet S Cheema, David F Claxton, Selina M Luger, Ryan J Mattison, Timothy R Wassenaar, Andrew S Artz, Charles A Schiffer, Mark R Litzow, Martin S Tallman
PURPOSE: Impaired response to erythropoietin underlies ineffective erythropoiesis and anemia in myelodysplastic syndromes (MDS). We investigated whether treatment with lenalidomide (LEN), which augments erythropoietin receptor signaling in vitro, can restore and improve hemoglobin response to epoetin (EPO) alfa in patients with lower-risk, non-del(5q) MDS who have anemia that is refractory to or have low probability of benefit from treatment with recombinant erythropoietin. METHODS: In a phase III, US intergroup trial, we randomly assigned patients to receive either LEN and EPO alfa or LEN alone following stratification by serum erythropoietin concentration and prior erythropoietin treatment...
January 13, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33439745/suggestion-for-research-design-noninferiority-design-in-elderly-patients-with-soft-tissue-sarcoma
#12
LETTER
Masaki Uchihara, Kenichi Yoshimura, Akihiko Shimomura, Yukino Kawamura, Chikako Shimizu
No abstract text is available yet for this article.
January 13, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33439695/duration-of-adjuvant-doublet-chemotherapy-3-or-6-months-in-patients-with-high-risk-stage-ii-colorectal-cancer
#13
Timothy J Iveson, Alberto F Sobrero, Takayuki Yoshino, Ioannis Souglakos, Fang-Shu Ou, Jeffrey P Meyers, Qian Shi, Axel Grothey, Mark P Saunders, Roberto Labianca, Takeharu Yamanaka, Ioannis Boukovinas, Niels H Hollander, Fabio Galli, Kentaro Yamazaki, Vassilis Georgoulias, Rachel Kerr, Eiji Oki, Sara Lonardi, Andrea Harkin, Gerardo Rosati, James Paul
PURPOSE: As oxaliplatin results in cumulative neurotoxicity, reducing treatment duration without loss of efficacy would benefit patients and healthcare providers. PATIENTS AND METHODS: Four of the six studies in the International Duration of Adjuvant Chemotherapy (IDEA) collaboration included patients with high-risk stage II colon and rectal cancers. Patients were treated (clinician and/or patient choice) with either fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or capecitabine and oxaliplatin (CAPOX) and randomly assigned to receive 3- or 6-month treatment...
January 13, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33439693/updated-overall-survival-and-pd-l1-subgroup-analysis-of-patients-with-extensive-stage-small-cell-lung-cancer-treated-with-atezolizumab-carboplatin-and-etoposide-impower133
#14
Stephen V Liu, Martin Reck, Aaron S Mansfield, Tony Mok, Arnaud Scherpereel, Niels Reinmuth, Marina Chiara Garassino, Javier De Castro Carpeno, Raffaele Califano, Makoto Nishio, Francisco Orlandi, Jorge Alatorre-Alexander, Ticiana Leal, Ying Cheng, Jong-Seok Lee, Sivuonthanh Lam, Mark McCleland, Yu Deng, See Phan, Leora Horn
PURPOSE: IMpower133 (ClinicalTrials.gov identifier: NCT02763579), a randomized, double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-ligand 1 [PD-L1]) to carboplatin plus etoposide (CP/ET) for first-line (1L) treatment of extensive-stage small-cell lung cancer (ES-SCLC) resulted in significant improvement in overall survival (OS) and progression-free survival (PFS) versus placebo plus CP/ET. Updated OS, disease progression patterns, safety, and exploratory biomarkers (PD-L1, blood-based tumor mutational burden [bTMB]) are reported...
January 13, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33439692/presumed-consent-with-opt-out-an-ethical-consent-approach-to-automatically-refer-patients-with-cancer-to-tobacco-treatment-services
#15
Joshua W Ohde, Zubin Master, Jon C Tilburt, David O Warner
No abstract text is available yet for this article.
January 13, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33439691/clinical-trials-for-real-world-elderly-patients-with-metastatic-soft-tissue-sarcomas-the-importance-of-study-design-and-patient-reported-outcomes
#16
LETTER
Eugenie Younger, Olga Husson, Winette T A van der Graaf
No abstract text is available yet for this article.
January 13, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33439690/misuse-of-noninferiority-margin-how-much-margin-is-ethical
#17
LETTER
Vinod Sharma, Akash Kumar
No abstract text is available yet for this article.
January 13, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33439689/melflufen-a-next-generation-nitrogen-mustard
#18
Sarah A Holstein, Jens Hillengass, Philip L McCarthy
No abstract text is available yet for this article.
January 13, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33439688/clinical-calculator-based-on-molecular-and-clinicopathologic-characteristics-predicts-recurrence-following-resection-of-stage-i-iii-colon-cancer
#19
Martin R Weiser, Meier Hsu, Philip S Bauer, William C Chapman, Iván A González, Deyali Chatterjee, Deepak Lingam, Matthew G Mutch, Ajaratu Keshinro, Jinru Shia, Efsevia Vakiani, Tsuyoshi Konishi, Yoshifumi Shimada, Zsofia Stadler, Neil H Segal, Andrea Cercek, Leonard Saltz, Rona Yaeger, Anna Varghese, Maria Widmar, Iris H Wei, Emmanouil P Pappou, J Joshua Smith, Garrett Nash, Philip Paty, Julio Garcia-Aguilar, Mithat Gonen
PURPOSE: Clinical calculators and nomograms have been endorsed by the American Joint Committee on Cancer (AJCC), as they provide the most individualized and accurate estimate of patient outcome. Using molecular and clinicopathologic variables, a third-generation clinical calculator was built to predict recurrence following resection of stage I-III colon cancer. METHODS: Prospectively collected data from 1,095 patients who underwent colectomy between 2007 and 2014 at Memorial Sloan Kettering Cancer Center were used to develop a clinical calculator...
January 13, 2021: Journal of Clinical Oncology
https://read.qxmd.com/read/33439687/reply-to-e-younger-et-al-v-sharma-et-al-and-m-uchihara-et-al
#20
Viktor Grünwald, Xiaofei Liu, Markus Schuler, Sebastian Bauer
No abstract text is available yet for this article.
January 13, 2021: Journal of Clinical Oncology
journal
journal
20146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"